Charles River Labs Downgraded at Argus on Cautious Biotech Spending
These Nike Analysts Are No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Demystifying Charles River: Insights From 4 Analyst Reviews
During the last three months, 4 analysts shared their evaluations of Charles River (NYSE:CRL), revealing diverse outlooks from bullish to bearish.The table below offers a condensed view of their recen
Argus Research Downgrades Charles River(CRL.US) to Hold Rating
Argus Research analyst David Toung downgrades $Charles River(CRL.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 62.0% and a total average return of 9.3% over the p
Charles River Labs Cut to Hold From Buy by Argus Research
Charles River Labs Cut to Hold From Buy by Argus Research
Argus Downgrades Charles River Laboratories International to Hold From Buy
Charles River Laboratories International (CRL) has an average outperform rating and a price target range of $226 to $300, according to analysts polled by Capital IQ. Price: 207.00, Change: -0.35, Perc
Express News | Charles River Labs : Barclays Initiates Coverage With Equal-Weight Rating and Target Price $230
Barclays Maintains Charles River(CRL.US) With Hold Rating, Maintains Target Price $230
Barclays analyst Luke Sergott maintains $Charles River(CRL.US)$ with a hold rating, and maintains the target price at $230.According to TipRanks data, the analyst has a success rate of 40.5% and a tot
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
Barclays Initiates Charles River(CRL.US) With Hold Rating, Announces Target Price $230
Barclays analyst Luke Sergott initiates coverage on $Charles River(CRL.US)$ with a hold rating, and sets the target price at $230.According to TipRanks data, the analyst has a success rate of 40.5% an
Express News | Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration With Gates Institute at University of Colorado Anschutz Medical Campus
Is Weakness In Charles River Laboratories International, Inc. (NYSE:CRL) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Charles River Laboratories International (NYSE:CRL) has had a rough three months with its share price down 20%. However, a closer look at its sound financials might cause you to think again. Given t
Just two shots a year, 100% effective! The market cap of the AIDS drug manufacturer soared by 48.3 billion.
The test results are impressive.
Charles River Associates (CRA) to Present at Noble Capital Markets Virtual Conference
Charles River Associates (CRA) Strengthens Its Energy Practice
Charles River Associates (NASDAQ:CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that Christine Oumansour has joined the company as a Vice President in the
Charles River and Captain T Cell Sign Vector Production Agreement
Charles River Laboratories, Captain T Cell Enter Manufacturing Deal
Charles River Laboratories (CRL) and Captain T Cell said Monday that they have entered into a plasmid DNA and retrovirus vector production program deal. Captain T Cell will use plasmid and viral vecto
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial Charles River Laboratories International, Inc. (NYSE:CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin,
Express News | Charles River Laboratories International Inc : Baird Raises Target Price to $271 From $270
Charles River and Octaura Launch Two-Way Interface for Simplified Syndicated Loan Trading